Back to search

Article

One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective study

2023-02-02

Abstract excerpt

<title>Abstract</title> <p>Anti-tumor necrosis factor alpha (anti-TNFα) inhibitors are used extensively for the management of moderate to severe inflammatory bowel disease (IBD) in both adult and pediatric patients. Unfortunately, not all patients show optimal response to induction therapy, while others lose their response over time, for reasons yet poorly understood. We report on a pharmacokinetic/pharmacogeneti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
26f83b0d-fcc7-5ea1-a75c-97656a1dac7c
DOI
10.21203/rs.3.rs-2528985/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective studyDOI 10.21203/rs.3.rs-2528985/v1
Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children.Semantic proximity
Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study.Semantic proximity
Association between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel Disease.Semantic proximity
HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapySemantic proximity
Genetic Polymorphisms on TNFA, TNFRSF1A, and TNFRSF1B Genes Predict the Effectiveness of Anti-TNF-α Treatment in Inflammatory Bowel Disease PatientsSemantic proximity
Treatment of Chronic Inflammatory Diseases – The Potential of PharmacogeneticsSemantic proximity
Extended Analysis Identifies Drug-Specific Association of 2 Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and InfliximabSemantic proximity
The genetics of IBD : from susceptibility to drug response and patient outcomeSemantic proximity
A cohort of anti-TNF treated Danish patients with inflammatory bowel disease, used for identifying genetic markers associated with treatment response.Semantic proximity
Molecular Insight into the Role of HLA Genotypes in Immunogenicity and Secondary Refractoriness to Anti-TNF Therapy in IBD PatientsSemantic proximity
Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients.Semantic proximity
Pharmacogenetics of Inflammatory Bowel DiseaseSemantic proximity
Select a neighboring publication to make it the new centre.